Solling ASK, et al. – Researchers evaluated 67 postmenopausal women with osteoporosis to determine the consequences of zoledronic acid (ZOL) therapy in this patient population. Odanacatib (ODN), a cathepsin K inhibitor, for treatment of osteoporosis was discontinued due to an increased risk of cardiovascular events. Given the reversible nature of treatment, participants from the LOFT trial were offered treatment with ZOL. They observed an increase in CTX by 107 ± 9%, PINP by 102 ± 16%, osteocalcin by 32 ± 6%, and BSAP by 79 ± 37% between 3 and 12 months, with a rise in BMD at the lumbar spine by 2.8 ± 0.9% from baseline to month 12. However, no significant variation was noted in BMD at the total hip or femoral neck. The investigators also observed a decline in PTH and eGFR levels but an uptick in S-25-hydroxyvitamin D level. Overall, ZOL 5-mg treatment prevented bone loss in women who were previously treated with ODN therapy.